Determining the protective effects of Ma-Mu-Ran Antidiarrheal Capsules against acute DSS-induced enteritis using 16S rRNA gene sequencing and fecal metabolomics

Zheng, Sili; Zhang, Dongning; Duan, Yanfen; Huang, Fang; Han, Lintao; Mo, Guoyan

doi:10.1016/s1875-5364(22)60158-4

Cited by 2 publications

(2 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, MMRAC has been analyzed using ultra‐performance liquid chromatography–tandem mass spectrometry, resulting in 577 chemical constituents. We will now screen for active ingredients based on this analysis (Zheng et al, 2022). We initially identified the primary ingredients of the MMRAC using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP; https://old.tcmsp-e.com/index.php) and the Integrative Pharmacology‐Based Research Platform of Traditional Chinese Medicine (TCMIP; http://www.tcmip.cn/TCMIP/index.php/Home/) to screen for active components.…”

Section: Methodsmentioning

confidence: 99%

“…Currently, MMRAC has been analyzed using ultra-performance liquid chromatography-tandem mass spectrometry, resulting in 577 chemical constituents. We will now screen for active ingredients based on this analysis (Zheng et al, 2022). We initially identified the primary ingredients of the MMRAC using the Traditional Chinese to screen for active components.…”

Section: Network Pharmacology Analysismentioning

confidence: 99%

See 1 more Smart Citation

Integrated network pharmacology and metabolomics analyses of the mechanism underlying the efficacy of Ma‐Mu‐Ran Antidiarrheal Capsules against dextran sulfate sodium–induced ulcerative colitis

Huang,

Duan,

Zheng

et al. 2023

Biomedical Chromatography

Self Cite

View full text Add to dashboard Cite

The current study utilizes a comprehensive network pharmacology and metabolomics analysis to investigate the mechanism of action of Ma‐Mu‐Ran Antidiarrheal Capsules (MMRAC) for the treatment of ulcerative colitis (UC). In this study, we established a mouse model of UC using dextran sulfate sodium. Colonic tissues were collected from mice and then subjected to hematoxylin and eosin staining, as well as histopathological analysis, to assess the therapeutic effect of MMRAC. Furthermore, we assessed the mechanisms through which MMRAC combats UC by employing integrated metabolomics and network pharmacology strategies. Lastly, we validated the key targets identified through western blot and molecular docking. An integrated network of metabolomics and network pharmacology was constructed using Cytoscape to identify eight endogenous metabolites involved in the therapeutic action of MMRAC on UC. Further comprehensive analyses were focused on four key targets and their associated core metabolites and pathways. The results of western blot and molecular docking demonstrated that MMRAC could modulate key targets and their expression levels. The cumulative results indicated that MMRAC restored intestinal function in UC, reduced inflammatory responses, and alleviated oxidative stress by influencing the methionine and cysteine metabolic pathways, as well as the urea cycle. In addition, it had an impact on arginine, proline, glutamate, aspartate, and asparagine metabolic pathways and their associated targets.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Network Pharmacology Analysismentioning

confidence: 99%

Integrated network pharmacology and metabolomics analyses of the mechanism underlying the efficacy of Ma‐Mu‐Ran Antidiarrheal Capsules against dextran sulfate sodium–induced ulcerative colitis

Huang,

Duan,

Zheng

et al. 2023

Biomedical Chromatography

Self Cite

View full text Add to dashboard Cite

show abstract

Mechanism of Action of Qingrekasen Granules in Alleviating Nephrotic Syndrome Evaluated by a Multi-Omics Approach

Wang,

Dai,

Huang

et al. 2024

Natural Product Communications

View full text Add to dashboard Cite

Objectives In this study, the efficacy of and mechanism of Qingrekasen Granules (QRKSG) is evaluated by metabolomics and transcriptomics using adriamycin (ADR)-induced nephrotic syndrome (NS) in rat model. Methods The model, benazepril, and QRKSG group received a single injection of 6.5 mg/kg ADR via the tail vein of the rats. The untreated group received an equal saline injection. The administration of drugs by gavage began after completing the modeling for one week. Benazepril was given at 0.9 mg/kg/d to the benazepril group and QRKSG was given at 1.62 g/kg/d to the QRKSG group. During gavage, 24 h urine was collected weekly. After four weeks of gavage, rats were anesthetized, and we collected the serum, feces, and kidney samples. The protective effect of QRKSG on NS was assessed by the detection of proteins in the urine at 24 h and serum biochemical indexes, as well as histopathological observation, TUNEL assay, and Western Blot of kidney samples. Moreover, gas chromatography-mass spectrometry (GC-MS) metabolomics sequencing of kidney metabolites helped investigate the significant differential metabolites produced by QRKSG that are implicated in ameliorating the pathological damage to the kidneys of NS rats. Subsequently, the significant targets of QRKSG that had an impact on the action of drugs were investigated by a transcriptome sequencing analysis. The correlation between both sets was also investigated. In addition, the effect of QRKSG on the gut microbiota of NS rats was investigated. Finally, the core targets were validated by molecular docking. Results The results indicated that QRKSG possess significant renoprotective effects in NS rats by reversing the abnormal urinary protein content and serum biochemical disorders, as well as improving renal pathological damage. Multiple genes and metabolites were shown to be back-regulated after QRKSG delivery, based on further multi-omics studies. The integrated metabolomics and transcriptomics analysis showed that QRKSG alleviated NS mainly by regulating amino acid metabolic pathways. Gut microbiota analysis demonstrated that QRKSG could alleviate NS by improving gut microbiota. The molecular docking results showed good binding ability of the QRKSG active ingredient to the core target, and among them, the ingredients with the best docking effect were mainly flavonoids and phenolic acid ingredients. The combined metabolomics and transcriptomics study findings were validated through a TUNEL assay and a Western Blot analysis. Conclusion We have concluded that ADR-induced NS in rats can be treated with QRKSG. The mechanisms used by QRKSG to reduce the symptoms of NS are through the multi-component, multi-target, and multi-pathway therapeutic modulation of inflammation, oxidative stress, energy homeostasis, and apoptosis. Additionally, QRKSG could alleviate NS by regulating gut microbiota.

show abstract

Determining the protective effects of Ma-Mu-Ran Antidiarrheal Capsules against acute DSS-induced enteritis using 16S rRNA gene sequencing and fecal metabolomics

Cited by 2 publications

References 70 publications

Integrated network pharmacology and metabolomics analyses of the mechanism underlying the efficacy of Ma‐Mu‐Ran Antidiarrheal Capsules against dextran sulfate sodium–induced ulcerative colitis

Integrated network pharmacology and metabolomics analyses of the mechanism underlying the efficacy of Ma‐Mu‐Ran Antidiarrheal Capsules against dextran sulfate sodium–induced ulcerative colitis

Mechanism of Action of Qingrekasen Granules in Alleviating Nephrotic Syndrome Evaluated by a Multi-Omics Approach

Contact Info

Product

Resources

About